NCT01419184View on ClinicalTrials.gov

Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA

PHASE4CompletedINTERVENTIONAL

Enrollment

250

Participants

Timeline

Start Date

September 9, 2011

Primary Completion Date

September 1, 2012

Study Completion Date

October 5, 2012

Conditions

Staphylococcal Skin Infections

Interventions

DRUG

Daptomycin

DRUG

Vancomycin

Trial Locations (26)

Unknown

Mobile

Chula Vista

Escondido

La Mesa

Oceanside

Augusta

Decatur

Waterloo

Topeka

Louisville

New Orleans

Worcester

Detroit

Royal Oak

Minneapolis

Las Vegas

Albany

East Meadow

Mineola

The Bronx

Winston-Salem

Columbus

Toledo

Rapid City

Austin

Ponce

All Listed Sponsors

lead

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT01419184 - Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA | Biotech Hunter | Biotech Hunter